OPKO Health (OPK) Expected to Announce Quarterly Earnings on Thursday

Key Points

• OPKO Health is expected to announce its Q2 2025 earnings on July 31st, with analysts predicting a loss of ($0.11) per share and revenue of $165.74 million.
• The company reported ($0.10) EPS in its previous earnings, falling short of estimates, and experienced a 13.7% decline in revenue compared to the same quarter last year.
• Investment ratings for OPKO Health include an "outperform" rating with a price target of $2.25 from Barrington Research, while Wall Street Zen has downgraded it to a "sell" rating.

OPKO Health (NASDAQ:OPK - Get Free Report) is expected to be releasing its Q2 2025 earnings data after the market closes on Thursday, July 31st. Analysts expect OPKO Health to post earnings of ($0.11) per share and revenue of $165.74 million for the quarter.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.03). The company had revenue of $149.90 million for the quarter, compared to analyst estimates of $163.13 million. OPKO Health had a negative net margin of 5.66% and a negative return on equity of 2.85%. The firm's revenue for the quarter was down 13.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.12) earnings per share. On average, analysts expect OPKO Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OPKO Health Price Performance

OPK stock traded down $0.01 during trading on Wednesday, hitting $1.34. The company had a trading volume of 2,192,280 shares, compared to its average volume of 3,905,469. The company has a fifty day moving average price of $1.34 and a two-hundred day moving average price of $1.48. The company has a current ratio of 2.49, a quick ratio of 2.28 and a debt-to-equity ratio of 0.25. The company has a market cap of $1.06 billion, a P/E ratio of -19.14 and a beta of 1.34. OPKO Health has a fifty-two week low of $1.21 and a fifty-two week high of $2.04.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on OPK shares. JPMorgan Chase & Co. started coverage on OPKO Health in a research note on Friday, April 25th. They set a "neutral" rating on the stock. LADENBURG THALM/SH SH upgraded shares of OPKO Health to a "strong-buy" rating in a research report on Tuesday, July 8th. Wall Street Zen lowered shares of OPKO Health from a "hold" rating to a "sell" rating in a report on Monday, May 5th. HC Wainwright restated a "buy" rating and issued a $3.00 price objective on shares of OPKO Health in a report on Monday, April 7th. Finally, Barrington Research reissued an "outperform" rating and issued a $2.25 price target on shares of OPKO Health in a research note on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $2.75.

Institutional Trading of OPKO Health

Several hedge funds have recently bought and sold shares of OPK. Millennium Management LLC increased its holdings in OPKO Health by 39.2% during the first quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company's stock worth $10,602,000 after buying an additional 1,798,385 shares during the last quarter. Goldman Sachs Group Inc. increased its position in OPKO Health by 4.2% during the first quarter. Goldman Sachs Group Inc. now owns 4,001,214 shares of the biotechnology company's stock worth $6,642,000 after buying an additional 161,394 shares during the last quarter. AQR Capital Management LLC increased its position in OPKO Health by 466.7% during the first quarter. AQR Capital Management LLC now owns 1,608,906 shares of the biotechnology company's stock worth $2,671,000 after buying an additional 1,324,988 shares during the last quarter. Cubist Systematic Strategies LLC increased its position in OPKO Health by 2,369.9% during the first quarter. Cubist Systematic Strategies LLC now owns 119,223 shares of the biotechnology company's stock worth $198,000 after buying an additional 114,396 shares during the last quarter. Finally, Caxton Associates LLP acquired a new position in OPKO Health during the first quarter worth approximately $130,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.